Profile data is unavailable for this security.
About the company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
- Revenue in USD (TTM)5.73m
- Net income in USD-12.89m
- Incorporated1997
- Employees20.00
- LocationPlus Therapeutics Inc4200 Marathon Blvd., Suite 200AUSTIN 78756United StatesUSA
- Phone+1 (858) 458-0900
- Fax+1 (302) 636-5454
- Websitehttp://www.plustherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adial Pharmaceuticals Inc | 0.00 | -13.03m | 6.53m | 4.00 | -- | 1.11 | -- | -- | -4.49 | -4.50 | 0.00 | 0.9185 | 0.00 | -- | -- | 0.00 | -272.04 | -182.35 | -316.95 | -235.45 | -- | -- | -- | -- | -- | -16.22 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -14.93m | 6.56m | 10.00 | -- | 3.97 | -- | -- | -8.49 | -8.49 | 0.00 | 0.0957 | 0.00 | -- | -- | 0.00 | -210.77 | -133.14 | -475.23 | -181.26 | -- | -- | -- | -- | -- | -40.02 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -14.23m | 6.59m | 29.00 | -- | -- | -- | -- | -3.46 | -3.46 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -369.22 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -35.87 | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| NLS Pharmaceutics AG | 0.00 | -6.60m | 6.66m | 3.00 | -- | -- | -- | -- | -6.72 | -6.72 | 0.00 | -9.40 | 0.00 | -- | -- | 0.00 | -380.82 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -27.20 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 6.79m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -6.93m | 6.85m | 16.00 | -- | 2.39 | -- | -- | -2.21 | -2.21 | 0.00 | 0.8829 | 0.00 | -- | -- | 0.00 | -94.60 | -- | -128.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 354.91k | -545.87k | 6.86m | 2.00 | -- | -- | -- | 19.33 | -0.00005 | -0.00005 | 0.00003 | -0.0001 | 8.98 | -- | 15.71 | 177,455.00 | -1,381.60 | -- | -- | -- | 87.28 | -- | -153.81 | -- | -- | -2.16 | -- | -- | -21.46 | -- | 36.92 | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -13.24m | 6.91m | 7.00 | -- | -- | -- | -- | -8.82 | -8.82 | 0.00 | -0.4198 | 0.00 | -- | -- | 0.00 | -198.45 | -87.52 | -594.46 | -116.56 | -- | -- | -- | -- | -- | -128.86 | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 386.00k | -97.82m | 6.98m | 68.00 | -- | -- | -- | 18.07 | -3.03 | -3.03 | 0.0105 | -0.4145 | 0.0033 | -- | -- | 5,676.47 | -84.04 | -54.44 | -111.15 | -64.32 | -- | -- | -25,340.67 | -772.82 | -- | -179.01 | 1.37 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Biora Therapeutics Inc | 892.00k | -35.57m | 7.07m | 58.00 | -- | -- | -- | 7.93 | -12.92 | -11.78 | 0.2163 | -28.99 | 0.0363 | -- | 1.06 | 15,379.31 | -144.59 | -122.84 | -- | -369.01 | -- | -- | -3,988.12 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Plus Therapeutics Inc (USA) | 5.73m | -12.89m | 7.08m | 20.00 | -- | -- | -- | 1.24 | -2.42 | -2.42 | 0.988 | -0.8775 | 0.5653 | -- | -- | 286,250.00 | -127.22 | -59.18 | -- | -133.04 | -- | -- | -225.07 | -470.45 | -- | -4.31 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| ABVC Biopharma Inc | 509.80k | -8.24m | 7.14m | 16.00 | -- | 0.8363 | -- | 14.00 | -0.9744 | -0.9744 | 0.0508 | 0.6576 | 0.0328 | -- | 1.60 | 31,862.50 | -56.14 | -103.38 | -88.09 | -231.54 | 72.54 | 76.25 | -1,710.03 | -2,019.89 | -- | -2.62 | 0.1856 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.19m | -10.42m | 7.19m | 13.00 | -- | 1.18 | -- | 2.26 | -27.94 | -27.94 | 1.42 | 1.39 | 0.3121 | 1.93 | 5.56 | 245,228.50 | -102.35 | -71.59 | -255.70 | -144.36 | 48.31 | -- | -327.90 | -565.48 | 1.01 | -- | 0.0775 | -- | 147.58 | 596.39 | 4.47 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 35.69k | -8.25m | 7.57m | 7.00 | -- | 2.04 | -- | 212.12 | -0.3853 | -0.3853 | 0.0016 | 0.1215 | 0.0068 | -- | 4.94 | 5,098.57 | -158.03 | -- | -229.86 | -- | -- | -- | -23,124.35 | -- | -- | -27.40 | 0.00 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -27.03m | 7.60m | 42.00 | -- | 0.8825 | -- | -- | -1.03 | -1.03 | 0.00 | 0.2901 | 0.00 | -- | -- | 0.00 | -131.14 | -- | -200.57 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Plus Therapeutics Inc's reporting currency: US Dollar USD
11.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 30 Sep 2024 | 560.91k | 9.51% |
| Geode Capital Management LLCas of 30 Sep 2024 | 54.27k | 0.92% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 32.54k | 0.55% |
| Ashton Thomas Private Wealth LLCas of 30 Sep 2024 | 12.91k | 0.22% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.96k | 0.12% |
| Tower Research Capital LLCas of 30 Sep 2024 | 3.71k | 0.06% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2024 | 133.00 | 0.00% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2024 | 100.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 48.00 | 0.00% |
| Group One Trading LLCas of 30 Sep 2024 | 1.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
